Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dongyi He

Showing results (131-140 of 146) with videos related to

Pageof 15
Sort By:
Clinical Rheumatology|May 28, 2017
Clinical patterns and characteristics of ankylosing spondylitis in ChinaQiaoxia Qian, Xia Xu, Hongjun He, et al.
Frontiers in Genetics|November 15, 2021
MicroRNA Variants and HLA-miRNA Interactions are Novel Rheumatoid Arthritis Susceptibility FactorsShicheng Guo, Yehua Jin, Jieru Zhou, et al.
Frontiers in Pharmacology|December 28, 2020
Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time PointsJinmei Su, Mengtao Li, Lan He, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 23, 2023
Identification of Distinct Genetic Profiles of Palindromic Rheumatism Using Whole-Exome SequencingChenxiang Zheng, Fan Wang, Yue Sun, et al.
The Lancet. Rheumatology|January 17, 2024
IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trialHuji Xu, Zhijun Li, Jian Wu, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 21, 2020
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical TrialJinmei Su, Mengtao Li, Lan He, et al.
Clinical Rheumatology|October 28, 2021
Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 studyJinmei Su, Mengtao Li, Lan He, et al.
Rheumatology and Therapy|March 25, 2023
Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority StudyHua Ye, Shengyun Liu, Jian Xu, et al.
Clinical Rheumatology|March 29, 2018
Smoking quantity determines disease activity and function in Chinese patients with ankylosing spondylitisHui Zhang, Wei Wan, Jing Liu, et al.
Clinical and Experimental Rheumatology|September 6, 2018
Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 studyLiqi Bi, Yuhui Li, Lan He, et al.
Pageof 15

Showing results (131-140 of 146) with videos related to

Sort By:
Pageof 15
Clinical Rheumatology|May 28, 2017
Clinical patterns and characteristics of ankylosing spondylitis in ChinaQiaoxia Qian, Xia Xu, Hongjun He, et al.
Frontiers in Genetics|November 15, 2021
MicroRNA Variants and HLA-miRNA Interactions are Novel Rheumatoid Arthritis Susceptibility FactorsShicheng Guo, Yehua Jin, Jieru Zhou, et al.
Frontiers in Pharmacology|December 28, 2020
Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time PointsJinmei Su, Mengtao Li, Lan He, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 23, 2023
Identification of Distinct Genetic Profiles of Palindromic Rheumatism Using Whole-Exome SequencingChenxiang Zheng, Fan Wang, Yue Sun, et al.
The Lancet. Rheumatology|January 17, 2024
IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trialHuji Xu, Zhijun Li, Jian Wu, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 21, 2020
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical TrialJinmei Su, Mengtao Li, Lan He, et al.
Clinical Rheumatology|October 28, 2021
Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 studyJinmei Su, Mengtao Li, Lan He, et al.
Rheumatology and Therapy|March 25, 2023
Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority StudyHua Ye, Shengyun Liu, Jian Xu, et al.
Clinical Rheumatology|March 29, 2018
Smoking quantity determines disease activity and function in Chinese patients with ankylosing spondylitisHui Zhang, Wei Wan, Jing Liu, et al.
Clinical and Experimental Rheumatology|September 6, 2018
Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 studyLiqi Bi, Yuhui Li, Lan He, et al.
Pageof 15